Mutational analysis of KRAS and NRAS genes should be performed in patients with metastatic colorectal carcinoma (CRC) who might benefit from a regimen containing an anti-EGFR monoclonal antibody (cetuximab, panitumumab) as first- or further- line treatment. The use of an anti-EGFR monoclonal antibody is not indicated in patients with mutations in exons 2 and 3 of KRAS gene and exons 2, 3 and 4 of NRAS gene.
Colon panel allows the parallel analysis of 216 mutations in the 4 major oncogenes involved in the pathogenesis of colorectal cancer (KRAS, BRAF, PIK3CA, NRAS). In the past two decades many of these mutations have been recognized as having predictive and prognostic value for specific targeted therapies.
These mutations include the sequences of codons 12, 13, 59, 61, 117, 146 of RAS genes whose predictive value for anti-EGFR monoclonal antibody therapy in colorectal cancer has been recognized in the results of the PRIME and PEAK clinical studies.
The test is performed by MALDI-TOF Mass Spectrometry combined with Single Base Extension technology. One of the main advantages of this technique is that it allows a complete mutational analysis of the sample with a much smaller quantity of DNA than is required for other methods. The kit also includes two controls (positive, negative) for each analytical session.
This method allows the optimization of turnaround time due to its high processivity, and owing to the fact that the sample can be comprehensively genotyped in a single session.
The tests are performed within 7working days from sample receipt.